Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | ELANE | P08246 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598018 | 0.89 | ALDH1A1 (0.45) | GABRA1GABRB2ELANECYP1B1ALDH1A1 | |
| SCHEMBL3244580 | 0.89 | GABRA1 (0.52) | GABRA1GABRB2ELANEKCNH2SCN5A | |
| SCHEMBL28190 | 0.89 | ALDH1A1 (0.45) | GABRA1GABRB2ELANECYP1B1ALDH1A1 | |
| SCHEMBL5598415 | 0.81 | ALDH1A1 (0.50) | GABRA1GABRB2ELANECYP1B1ALDH1A1 | |
| SCHEMBL11893017 | 0.78 | GABRA1 (0.54) | GABRA1GABRB2ELANECYP1B1NSD2 | |
| SCHEMBL31732993 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2ELANEKCNH2SCN5A | |
| SCHEMBL13745202 | 0.78 | TSHR (0.36) | ELANECYP1B1ALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL954995 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2ELANEKCNH2SCN5A | |
| SCHEMBL1538927 | 0.78 | ALDH1A1 (0.36) | ELANECYP1B1ALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL3283526 | 0.78 | ELANE (0.41) | GABRA1GABRB2ELANECYP1B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556229-B2 | Modification of peptides using a bis(thioether)arylbridge approach | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-31 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812047-B2 | 4-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2173719-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687811-A | 4-imidazolines and as the application of antidepressive | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| CN-101374516-A | Use of substituted 2-imidazole of imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012138-A1 | 4-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003867-A1 | 4-IMIDAZOLINES AND THEIR USE AS ANTIDEPRESSANTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012138-A1 | 4-IMIDAZOLINES | TAAR1, TAAR5, GPR119 | GABRA1 78/4885GABRB2 123/4885ELANE 4843/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | GABRA1 270/4885GABRB2 119/4885ELANE 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.